SRR15030850
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- XENOBIOTIC_METABOLISM+0.650
- BILE_ACID_METABOLISM+0.600
- FATTY_ACID_METABOLISM+0.560
- OXIDATIVE_PHOSPHORYLATION+0.540
- ADIPOGENESIS+0.470
- PEROXISOME+0.440
- COAGULATION+0.430
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.380
- HEME_METABOLISM+0.350
- CHOLESTEROL_HOMEOSTASIS+0.320
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.340
- WNT_BETA_CATENIN_SIGNALING-0.320
- PANCREAS_BETA_CELLS-0.220
- G2M_CHECKPOINT-0.200
- APICAL_JUNCTION-0.190
- MITOTIC_SPINDLE-0.190
- P53_PATHWAY-0.150
- TNFA_SIGNALING_VIA_NFKB-0.150
- E2F_TARGETS-0.080
- INFLAMMATORY_RESPONSE-0.080
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR15030845 | — | — | 0.900 |
| 2 | SRR15030885 | — | — | 0.859 |
| 3 | SRR15030860 | — | — | 0.849 |
| 4 | SRR4195672 | — | — | 0.825 |
| 5 | SRR4195657 | — | — | 0.822 |
| 6 | SRR15030876 | — | — | 0.817 |
| 7 | SRR4195645 | — | — | 0.805 |
| 8 | SNU878_LIVER | HCC | — | 0.770 |
| 9 | 838CD666-8E7E-417B-AA30-1197F9AE078D | — | — | 0.767 |
| 10 | SRR975594 | — | — | 0.759 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| XENOBIOTIC_METABOLISM | 0.650 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.600 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.560 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.540 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.470 | Inavolisib | — uncovered |
| PEROXISOME | 0.440 | Idelalisib | — uncovered |
| COAGULATION | 0.430 | Binimetinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.380 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.350 | Temsirolimus | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.320 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.280 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.280 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.220 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.210 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.150 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.140 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.130 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.120 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.110 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.070 | Inavolisib | — uncovered |